Evidence map›Paper›PMID 36204149›Full record

ArticleFrontiers in chemistry2022

Characterization of light chain c-terminal extension sequence variant in one bispecific antibody.

Jun Lin, Mengyu Xie, Dan Liu, Zhen Gao, Xiaoyan Zhao, Hongxia Ma, Sheng Ding, Shu Mei Li, Song Li, Yanling Liu and 10 more

Abstract read
In one paragraph

Article in Frontiers in chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jun LinDepartment of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai, China.
Mengyu XieGenor Biopharma Co., Ltd., Shanghai, China.
Dan LiuGenor Biopharma Co., Ltd., Shanghai, China.
Zhen GaoGenor Biopharma Co., Ltd., Shanghai, China.
Xiaoyan ZhaoGenor Biopharma Co., Ltd., Shanghai, China.
Hongxia MaGenor Biopharma Co., Ltd., Shanghai, China.
Sheng DingGenor Biopharma Co., Ltd., Shanghai, China.
Shu Mei LiGenor Biopharma Co., Ltd., Shanghai, China.
Song LiGenor Biopharma Co., Ltd., Shanghai, China.
Yanling LiuGenor Biopharma Co., Ltd., Shanghai, China.
Fang ZhouGenor Biopharma Co., Ltd., Shanghai, China.
Hao HuGenor Biopharma Co., Ltd., Shanghai, China.
Tao ChenGenor Biopharma Co., Ltd., Shanghai, China.
He ChenGenor Biopharma Co., Ltd., Shanghai, China.
Min XieGenor Biopharma Co., Ltd., Shanghai, China.
Bo YangGenor Biopharma Co., Ltd., Shanghai, China.
Jun ChengGenor Biopharma Co., Ltd., Shanghai, China.
Mingjun MaGenor Biopharma Co., Ltd., Shanghai, China.
Yanyang NanDepartment of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai, China.
Dianwen JuDepartment of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein modifications such as post-translational modifications (PTMs) and sequence variants (SVs) occur frequently during protein biosynthesis and have received great attention by biopharma industry and regulatory agencies. In this study, an aberrant peak near light chain (LC) was observed in the non-reduced capillary electrophoresis sodium dodecyl sulfate (nrCE-SDS) electrophoretogram during cell line development of one bispecific antibody (BsAb) product, and the detected mass was about 944 Da higher than LC. The corresponding peak was then enriched by denaturing size-exclusion chromatography (SEC-HPLC) and further characterized by nrCE-SDS and peptide mapping analyses.

Indexed as

aberrant splicingLC-MS/MSlight chainnon-reduced CE-SDSsequence variant

Identifiers

PMID36204149
PMCPMC9530627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.